Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Capital Leases (2016 - 2018)

Gsk has reported Capital Leases over the past 3 years, most recently at $56.6 million for Q4 2018.

  • Quarterly results put Capital Leases at $56.6 million for Q4 2018, down 0.83% from a year ago — trailing twelve months through Dec 2018 was $56.6 million (down 0.83% YoY), and the annual figure for FY2018 was $58.8 million, up 6.08%.
  • Capital Leases for Q4 2018 was $56.6 million at Gsk, down from $57.1 million in the prior quarter.
  • Over the last five years, Capital Leases for GLAXF hit a ceiling of $57.1 million in Q4 2017 and a floor of $51.0 million in Q4 2016.
  • Median Capital Leases over the past 3 years was $56.6 million (2018), compared with a mean of $54.9 million.
  • Biggest five-year swings in Capital Leases: rose 12.0% in 2017 and later decreased 0.83% in 2018.
  • Gsk's Capital Leases stood at $51.0 million in 2016, then grew by 12.0% to $57.1 million in 2017, then decreased by 0.83% to $56.6 million in 2018.
  • The last three reported values for Capital Leases were $56.6 million (Q4 2018), $57.1 million (Q4 2017), and $51.0 million (Q4 2016) per Business Quant data.